title: Pericardial Effusion Following Hematopoietic Cell Transplantation in Children and Young Adults Is Associated with Increased Risk of Mortality.
abstract: Hematopoietic cell transplantation (HCT) is curative for many pediatric malignant and nonmalignant disorders but is associated with significant morbidity and mortality, including the development of pericardial effusion (PEF). We report the results of a retrospective chart review performed to assess the incidence, risk factors, and prognostic significance of PEF in pediatric HCT recipient at Lucile Packard Children's Hospital of Stanford University. A total of 119 patients undergoing HCT between January 2010 and December 2013 were selected through the hospital's Pediatric Stem Cell Transplant Program database. A retrospective chart review, including review of documentation, correspondence, imaging reports, laboratory values, and death records, was performed to collect data. The overall incidence of PEF in our population was 21%. Risk factors for the development of PEF included unrelated donor transplants and cord blood as the stem cell source (P = .005), whereas HLA mismatch approached significance (P = .05). The risk for development of PEF was found to not be significantly associated with acute or chronic graft-versus-host disease (GVHD), age at transplantation, sex, conditioning regimen, or viral reactivation status. Of interest, 6 of the 119 patients were found to have transplant-associated thrombotic microangiopathy (TA-TMA). Four of those 6 patients developed PEF, suggesting TA-TMA as a risk factor for PEF. Eight of the 25 patients who developed PEF (32%) required pericardiocentesis. Five out of the 8 patients requiring pericardiocentesis died owing to causes unrelated to the procedure or to PEF itself. Pericardial fluid testing in 4 of these patients (50%) was positive for human herpesvirus 6, Epstein-Barr virus, cytomegalovirus, and/or adenovirus. Finally, of significant interest, patients with PEF had a statistically significant higher likelihood of mortality compared with those without PEF (44% versus 17%; P = .007).
authors.affiliation: Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, California.
authors.forename: Kelly
authors.initials: K
authors.lastname: Cox
authors.affiliation: Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, California.
authors.forename: Rajesh
authors.initials: R
authors.lastname: Punn
authors.affiliation: Department of Pediatrics, Division of Stem Cell Transplant and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Weiskopf
authors.affiliation: Department of Pathology, Stanford University School of Medicine, Stanford, California; Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California.
authors.forename: Benjamin A
authors.initials: BA
authors.lastname: Pinsky
authors.affiliation: Department of Pediatrics, Division of Stem Cell Transplant and Regenerative Medicine, Stanford University School of Medicine, Stanford, California. Electronic address: ksandhya@stanford.edu.
authors.forename: Sandhya
authors.initials: S
authors.lastname: Kharbanda
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010490:Pericardial Effusion / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D055815:Young Adult
keywords: Hematopoietic cell transplantation; Pericardial effusion